ATE271379T1 - System zur verzögerten freisetzung säurelabiler substanzen - Google Patents

System zur verzögerten freisetzung säurelabiler substanzen

Info

Publication number
ATE271379T1
ATE271379T1 AT97946676T AT97946676T ATE271379T1 AT E271379 T1 ATE271379 T1 AT E271379T1 AT 97946676 T AT97946676 T AT 97946676T AT 97946676 T AT97946676 T AT 97946676T AT E271379 T1 ATE271379 T1 AT E271379T1
Authority
AT
Austria
Prior art keywords
delayed release
barrier
omeprazole
pulsatile
acid label
Prior art date
Application number
AT97946676T
Other languages
English (en)
Inventor
Vinay K Sharma
Original Assignee
Wockhardt Europ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Europ Ltd filed Critical Wockhardt Europ Ltd
Application granted granted Critical
Publication of ATE271379T1 publication Critical patent/ATE271379T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT97946676T 1996-11-06 1997-11-05 System zur verzögerten freisetzung säurelabiler substanzen ATE271379T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74098196A 1996-11-06 1996-11-06
PCT/US1997/020851 WO1998019668A1 (en) 1996-11-06 1997-11-05 Delayed delivery system for acid-sensitive drugs

Publications (1)

Publication Number Publication Date
ATE271379T1 true ATE271379T1 (de) 2004-08-15

Family

ID=24978866

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946676T ATE271379T1 (de) 1996-11-06 1997-11-05 System zur verzögerten freisetzung säurelabiler substanzen

Country Status (7)

Country Link
EP (1) EP0941074B1 (de)
AT (1) ATE271379T1 (de)
AU (1) AU5179898A (de)
DE (1) DE69729950T2 (de)
NO (1) NO992186L (de)
WO (1) WO1998019668A1 (de)
ZA (1) ZA979937B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
EP1108425B1 (de) * 1999-12-16 2005-06-08 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Neue stabile mehreinheitliche substituierte Benzimidazole enthaltende pharmazeutische Präparate
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US7300668B2 (en) 2001-10-29 2007-11-27 Massachusetts Institute Of Technology System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US8449911B2 (en) 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
CA2547398A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
JP2008502740A (ja) * 2004-06-15 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド ベンズイミダゾール化合物の安定医薬製剤
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
CN101389317A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
ZA200805646B (en) * 2005-12-28 2009-12-30 Takeda Pharmaceutical Controlled release solid preparation
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CN104721168A (zh) * 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
PL2124966T3 (pl) 2007-02-01 2016-01-29 Iams Europe B V Sposób zmniejszania reakcji zapalnej i stresu u ssaków za pomocą antymetabolitów glukozy, awokado lub ekstraktów awokado
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.

Also Published As

Publication number Publication date
DE69729950T2 (de) 2005-07-28
WO1998019668A1 (en) 1998-05-14
ZA979937B (en) 1999-05-18
NO992186D0 (no) 1999-05-05
EP0941074A1 (de) 1999-09-15
NO992186L (no) 1999-05-05
AU5179898A (en) 1998-05-29
EP0941074B1 (de) 2004-07-21
DE69729950D1 (de) 2004-08-26

Similar Documents

Publication Publication Date Title
ATE271379T1 (de) System zur verzögerten freisetzung säurelabiler substanzen
RU2111743C1 (ru) Многокомпонентная дозированная форма с контролируемым выделением активного ингредиента
KR101078636B1 (ko) 약학 활성원의 지연 및 조절된 방출을 위한 생약 미세입자구강 제제
US5834023A (en) Diltiazem controlled release formulation
DK0754452T3 (da) Farmaceutisk præparat i form af en overtrukket kapsel, der frigives i den nedre del af fordøjelsessystemet
RU99126869A (ru) Фармацевтический препарат омепразола
DE60021604D1 (de) Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
MX9500885A (es) Preparacion farmaceutica para administracion oral.
DE59710629D1 (de) Stabile arzneiform mit benzimidazolderivaten als wirkstoff zur oralen verabreichung und verfahren zu ihrer herstellung
ATE251899T1 (de) Pharmazeutische dosierungsform zur freisetzung im colon
ATE316784T1 (de) Pharmazeutische formulierung für den wirkstoff budesonid
ATE205705T1 (de) Arzneimittel zum wirkstoff - targetting in den dickdarm
NO20003640L (no) Ny doseringsform
EP0725645A1 (de) ZUSAMMENSETZUNGEN ZUR VERWENDUNG BEI DER REGULATION SUBNORMALER pH-WERTE IM INTESTINALTRAKT UND ZUR BEHANDLUNG VON DARMERKRANKUNGEN
RU2006101082A (ru) Фармацевтическая композиция с набухающим покрытием
BRPI0719319A2 (pt) Liberação colônica usando contas de zn/pectina com um revestimento de eudragit
HASEGAWA et al. Application of solid dispersions of nifedipine with enteric coating agent to prepare a sustained-release dosage form
WO2021115648A1 (en) Dosage form comprising an alkaline agent and an enteric coating layer
DE60035421D1 (de) Chitosanpulver enthaltende feste zubereitungen und verfahren zu deren herstellung
Allen et al. Effect of single dose of omeprazole on the gastrointestinal peptide response to food
WO2021030474A1 (en) Articles and methods for administration of therapeutic agents
MX9703918A (es) Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior.
CN214018532U (zh) 一种庆大霉素单抗用胶囊
CN120732809B (zh) 一种抗脆碎性好的肠溶空心胶囊及其制备工艺
JPH06256166A (ja) 薬物放出制御製剤

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties